Docteur RENE PRATS

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain)

  Archives of disease in childhood · 2024

  📚 86 citations🎯 RCR 19.56Top 1% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  BackgroundIn Catalonia, infants under 6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse nirsevimab’s effectiveness across primary and hospital care outcomes.MethodsRetrospective cohort study from 1 October 2023 to 31 January 2024, including all infants born between April and September 2023. We established two cohorts based on nirsevimab administration (immunised and non-immunised). We followed individuals until the earliest moment of an outcome—RSV infection, primary care attended bronchiolitis and pneumonia, hospital emergency visits due to bronchiolitis, hospital admission or intensive care unit (ICU) admission due to RSV bronchiolitis—death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate HRs and their 95% CIs.ResultsAmong 26 525 infants, a dose of nirsevimab led to an adjusted HR for hospital admission due to RSV bronchiolitis of 0.124 (95% CI: 0.086 to 0.179) and an adjusted HR for ICU admission of 0.099 (95% CI: 0.041 to 0.237). Additionally, the adjusted HRs observed for emergency visits were 0.446 (95% CI: 0.385 to 0.516) and 0.393 (95% CI: 0.203 to 0.758) for viral pneumonia, 0.519 (95% CI: 0.467 to 0.576) for bronchiolitis attended in primary care and 0.311 (95% CI: 0.200 to 0.483) for RSV infection.ConclusionWe demonstrated nirsevimab’s effectiveness with reductions of 87.6% and 90.1% in hospital and ICU admissions, respectively. These findings offer crucial guidance for public health authorities in implementing RSV immunisation campaigns.

• 2

  Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-related Outcomes in Hospital Care Settings: A Seasonal Cohort Study of Infants in Catalonia, Spain

  The Pediatric infectious disease journal · 2025

  📚 15 citations🎯 RCR 6.20🔓 Open Access

  Lire l'abstract Crossref ↓

  Background: In Catalonia, infants <6 months old were eligible to receive nirsevimab, a novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyze nirsevimab’s effectiveness in hospital-related outcomes of the seasonal cohort (born during the RSV epidemic from October to January 2024) and compared them with the catch-up cohort (born from April to September 2023). Methods: Retrospective cohort study of all infants born between October 1, 2023, and January 21, 2024, according to their immunization with nirsevimab (immunized and nonimmunized). We followed individuals until the earliest of an outcome—hospital emergency visits, hospital admission or pediatric intensive care unit (PICU) admission due to RSV-associated or all-causes bronchiolitis—death or the end of the study. We used the Kaplan-Meier estimator and fitted Cox regression models using a calendar time scale to estimate hazard ratios (HRs) and their 95% confidence interval (CI). Sensitivity analysis was performed through matching. Results: Among 15,341 infants, a dose of nirsevimab led to an adjusted HR for hospital admission, PICU admission and emergency visits due to RSV bronchiolitis of 0.26 (95% CI: 0.17–0.39), 0.15 (95% CI: 0.07–0.28) and 0.46 (95% CI: 0.23–0.90), respectively. For all-causes bronchiolitis, the former adjusted HRs were 0.45 (95% CI: 0.31–0.63), 0.23 (95% CI: 0.13–0.41) and 0.49 (95% CI: 0.35–0.68), respectively. Conclusions: Nirsevimab was associated with reductions of 74% and 85% hospitalizations and PICU admissions regarding RSV-associated bronchiolitis, respectively. These percentages are slightly lower than those for the catch-up cohort. This information may help the implementation of RSV-immunization campaigns by public health authorities.

• 3

  Central apnea in a sporadic case of Creutzfeldt-Jakob disease with brainstem involvement

  Acta neurologica Belgica · 2010

  📚 5 citations

Publications scientifiques (5) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche